Literature DB >> 21087393

Risk group stratification to predict recurrence after transurethral resection in Japanese patients with stage Ta and T1 bladder tumours: validation study on the European Association of Urology guidelines.

Shigeru Sakano1, Hideyasu Matsuyama, Kimio Takai, Satoru Yoshihiro, Yoriaki Kamiryo, Satoshi Shirataki, Yoshitaka Kaneda, Osamu Hashimoto, Keiji Joko, Akinobu Suga, Mitsutaka Yamamoto, Shigeaki Hayashida, Yoshikazu Baba, Akihiko Aoki.   

Abstract

OBJECTIVE: • To validate the European Association of Urology (EAU) guidelines on risk group stratification to predict recurrence in Japanese patients with stage Ta and T1 bladder tumours. PATIENTS AND METHODS: • A cohort of 592 Japanese patients who were treated with transurethral resection (TUR) and histopathologically diagnosed with Ta and T1 urothelial carcinoma of the bladder were enrolled in this retrospective study. • The primary endpoint of the present study was recurrence-free survival, and the median follow-up duration was 37 months in recurrence-free survivors.
RESULTS: • Multivariate Cox proportional hazards regression analysis showed that the Eastern Cooperative Oncology Group performance status (ECOG PS), prior recurrence rate, number of tumours and T category were independent predictors of time to recurrence (P < 0.05). According to the EAU guidelines for predicting recurrence, the vast majority of Japanese patients were classified into intermediate risk. • The intermediate-risk patients were further divided into intermediate-low-risk and intermediate-high-risk subgroups based on the European Organization for Research and Treatment of Cancer risk table, and a significant difference in the recurrence-free survival rates was found between these subgroups (P < 0.001). • It was also found that patients with high risk combined with intermediate-high risk had significantly poorer recurrence-free survival rates than those with low risk combined with intermediate-low risk (P < 0.001).
CONCLUSIONS: • This is the first report on the ECOG PS as a potentially useful predictor for bladder tumour recurrence. • The risk group stratification of the EAU guidelines for recurrence might not be applicable to Japanese patients with Ta and T1 bladder tumours, but the subgroup classification of intermediate risk could be appropriate.
© 2010 THE AUTHORS. BJU INTERNATIONAL © 2010 BJU INTERNATIONAL.

Entities:  

Mesh:

Year:  2010        PMID: 21087393     DOI: 10.1111/j.1464-410X.2010.09850.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  6 in total

1.  Selection of adjuvant intravesical therapies using the European Organization for Research and Treatment of Cancer scoring system in patients at intermediate risk of non-muscle-invasive bladder cancer.

Authors:  Mitsuo Ofude; Yasuhide Kitagawa; Hiroshi Yaegashi; Kouji Izumi; Satoru Ueno; Yoshifumi Kadono; Hiroyuki Konaka; Atsushi Mizokami; Mikio Namiki
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-10       Impact factor: 4.553

2.  Development and Validation of a Novel Recurrence Risk Stratification for Initial Non-Muscle Invasive Bladder Cancer in the Han Chinese Population.

Authors:  Zhiyong Wang; Wansheng Gao; Jian Li; Tianen Wang; Man Zhu; Yu Duan
Journal:  J Cancer       Date:  2020-01-14       Impact factor: 4.207

3.  EORTC risk tables - their usefulness in the assessment of recurrence and progression risk in non-muscle-invasive bladder cancer in Polish patients.

Authors:  Edyta M Borkowska; Adam Jędrzejczyk; Piotr Marks; James W F Catto; Bogdan Kałużewski
Journal:  Cent European J Urol       Date:  2013-04-26

4.  Editorial comment.

Authors:  Sławomir Poletajew; Piotr Radziszewski
Journal:  Cent European J Urol       Date:  2013

5.  External validation of EORTC risk scores to predict recurrence after transurethral resection of brazilian patients with non -muscle invasive bladder cancer stages Ta and T1.

Authors:  Gilberto L Almeida; Wilson F S Busato; Carmen Marcondes Ribas; Jurandir Marcondes Ribas; Ottavio De Cobelli
Journal:  Int Braz J Urol       Date:  2016 Sep-Oct       Impact factor: 1.541

6.  Development and Validation of a Novel Recurrence Risk Stratification for Initial Non-muscle Invasive Bladder Cancer in Asia.

Authors:  Takeshi Ieda; Satoru Muto; Fumitaka Shimizu; Masataka Taguri; Shigeto Yanada; Kousuke Kitamura; Kazutaka Terai; Keisuke Saito; Tatsuya Ogishima; Masayoshi Nagata; Hisamitsu Ide; Takatsugu Okegawa; Yoshiaki Wakumoto; Yoshiro Sakamoto; Akira Tsujimura; Raizo Yamaguchi; Kikuo Nutahara; Shigeo Horie
Journal:  EBioMedicine       Date:  2016-09-02       Impact factor: 8.143

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.